DE3586972D1 - PURIFIED INTERLEUKIN-1. - Google Patents

PURIFIED INTERLEUKIN-1.

Info

Publication number
DE3586972D1
DE3586972D1 DE8585301752T DE3586972T DE3586972D1 DE 3586972 D1 DE3586972 D1 DE 3586972D1 DE 8585301752 T DE8585301752 T DE 8585301752T DE 3586972 T DE3586972 T DE 3586972T DE 3586972 D1 DE3586972 D1 DE 3586972D1
Authority
DE
Germany
Prior art keywords
new
amino acid
cloning vector
interleukin
daltons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585301752T
Other languages
German (de)
Other versions
DE3586972T2 (en
Inventor
Douglas P Cerretti
Iii Paul J Conlon
David J Cosman
Kenneth H Grabstein
Thomas P Hopp
Shirley R Kronheim
Alf D Larsen
Carl J March
Virginia L Price
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cistron Biotechnology Inc
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27542003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3586972(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/676,533 external-priority patent/US5484887A/en
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DE3586972D1 publication Critical patent/DE3586972D1/en
Publication of DE3586972T2 publication Critical patent/DE3586972T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

(1)Interleukin 1 (I), as a homogenous protein of molecular wt. about 17500 daltons and having a partial amino acid sequence of formula (II), is new. (2)Homogeneous human interleukin 1 consisting of a single protein species of molecular wt. of about 17500 daltons and having the following amino acid compsn. is new. The compsn. (amino acid and no. of residues/molecule, consists of Asp/Asn 14; Thr 8; Ser 11; Glu/Gln 22; Pro 6; Gly 11; Ala 8; Cys at least 1; Val 11; Met 4; Ile 6; Leu 11; Tyr 4; Phe 11; His 3; Lys 13; Arg 3. (3) Pure DNA encoding for the expression of human (I) molecules is new. (4) Recombinant DNA cloning vector comprising a CDNA sequence comprising the gene for (I) is new. (5)Recombinant DNA cloning vector comprising DNA as claimed in paragraph (3) above is new. (6)Host transformed by a cloning vector as defined in paragraphs (4) and (5) above is new.
DE8585301752T 1984-06-19 1985-03-13 PURIFIED INTERLEUKIN-1. Expired - Lifetime DE3586972T2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62220184A 1984-06-19 1984-06-19
US63500684A 1984-07-27 1984-07-27
US67455584A 1984-11-26 1984-11-26
US06/676,533 US5484887A (en) 1984-06-19 1984-11-30 Homogeneous interleukin 1
US68764684A 1984-12-31 1984-12-31

Publications (2)

Publication Number Publication Date
DE3586972D1 true DE3586972D1 (en) 1993-02-25
DE3586972T2 DE3586972T2 (en) 1993-07-08

Family

ID=27542003

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3588224T Expired - Lifetime DE3588224T2 (en) 1984-06-19 1985-03-13 Purified interleukin-1 and DNA encoding interleukin-1 and their preparation, such DNA-containing vectors and their preparation and use for transforming hosts which allow the expression of interleukin-1
DE8585301752T Expired - Lifetime DE3586972T2 (en) 1984-06-19 1985-03-13 PURIFIED INTERLEUKIN-1.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE3588224T Expired - Lifetime DE3588224T2 (en) 1984-06-19 1985-03-13 Purified interleukin-1 and DNA encoding interleukin-1 and their preparation, such DNA-containing vectors and their preparation and use for transforming hosts which allow the expression of interleukin-1

Country Status (10)

Country Link
EP (2) EP0456332B1 (en)
JP (3) JP3217698B2 (en)
AT (2) ATE84547T1 (en)
AU (1) AU579142B2 (en)
CA (2) CA1341433C (en)
DE (2) DE3588224T2 (en)
DK (2) DK168048B1 (en)
IE (1) IE61353B1 (en)
MX (1) MX9203654A (en)
NZ (1) NZ211386A (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998578A (en) * 1984-05-18 1999-12-07 New England Medical Center Hospitals, Inc. Biologically active fragments of IL-1β
EP0569687B1 (en) * 1984-05-18 2002-08-21 New England Medical Center Hospitals, Inc. Human IL-1 cDNA sequences encoding biologically-active human IL-1 proteins
DE3588241T2 (en) * 1984-05-18 2002-12-05 Massachusetts Institute Of Technology, Cambridge Human IL-1 cDNA sequences encoding biologically active human IL-1 proteins
US5342614A (en) * 1984-12-21 1994-08-30 Otsuka Pharmaceutical Co., Ltd. Method of treating arthritus or inflammation with IL-1β or derivatives thereof
DK172052B1 (en) * 1984-12-21 1997-09-29 Otsuka Pharma Co Ltd Antitumor active substance, method for its preparation, drug containing the substance, gene encoding the substance, vector containing the gene as well as recombinant microorganism transformed with such a vector
US6107465A (en) * 1984-12-21 2000-08-22 Otsuka Pharmaceutical Co., Ltd. IL-1β and derivatives thereof and drugs
DE3587605T2 (en) * 1984-12-25 1994-03-17 Dainippon Pharmaceutical Co Interleukin-1 and its derivative.
AU577856B2 (en) * 1985-01-17 1988-10-06 Immunex Corporation Cloning and characterization of the human interleukin 1 gene
DE3683186D1 (en) * 1985-04-25 1992-02-13 Hoffmann La Roche RECOMBINANT HUMANINTERLEUKIN-1.
US5831022A (en) * 1986-02-18 1998-11-03 Hoffmann-La Roche Inc. Purification of recombinant human IL-1α
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
US4801686A (en) * 1986-09-04 1989-01-31 Immunex Corporation Purification of recombinant interleukin-1
US5047505A (en) * 1987-01-27 1991-09-10 Du Pont Merck Pharmaceutical Company High level expression in E. coli of soluble mature HIL-1beta and derivatives with altered biological activity
US4894333A (en) * 1987-05-28 1990-01-16 Immunex Corporation Bovine interleukin-1α
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
GB9010356D0 (en) * 1990-05-09 1990-06-27 Ciba Geigy Ag Maturation of hemopoietic cells
DE69229252T2 (en) * 1991-08-16 1999-12-16 Merck & Co., Inc. DNA encoding the interleukin-1B precursor converting enzyme
CA2469492C (en) * 2001-12-11 2012-10-16 University Of Medicine And Dentistry Of New Jersey Diagnostic methods for protein profiling
KR20090052355A (en) * 2006-08-14 2009-05-25 시코르, 인크. Highly pure pemetrexed diacid and processes for the preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378128D1 (en) * 1982-04-20 1988-11-03 Sloan Kettering Inst Cancer Purification of interleukin 2
DE3588241T2 (en) * 1984-05-18 2002-12-05 Massachusetts Institute Of Technology, Cambridge Human IL-1 cDNA sequences encoding biologically active human IL-1 proteins
DK172052B1 (en) * 1984-12-21 1997-09-29 Otsuka Pharma Co Ltd Antitumor active substance, method for its preparation, drug containing the substance, gene encoding the substance, vector containing the gene as well as recombinant microorganism transformed with such a vector
AU577856B2 (en) * 1985-01-17 1988-10-06 Immunex Corporation Cloning and characterization of the human interleukin 1 gene

Also Published As

Publication number Publication date
DE3588224D1 (en) 2000-09-14
ATE195344T1 (en) 2000-08-15
IE850614L (en) 1986-09-08
NZ211386A (en) 1989-04-26
DK168048B1 (en) 1994-01-24
DK37293D0 (en) 1993-03-30
DK110485A (en) 1985-12-20
EP0456332B1 (en) 2000-08-09
JP2000060577A (en) 2000-02-29
EP0456332A1 (en) 1991-11-13
JP3009381B2 (en) 2000-02-14
JP3217698B2 (en) 2001-10-09
DK37293A (en) 1993-03-30
ATE84547T1 (en) 1993-01-15
EP0165654A2 (en) 1985-12-27
JPH10279598A (en) 1998-10-20
DE3586972T2 (en) 1993-07-08
IE61353B1 (en) 1994-11-02
CA1341433C (en) 2003-06-24
DE3588224T2 (en) 2001-10-25
JPH09118697A (en) 1997-05-06
AU3986385A (en) 1986-01-02
EP0165654B1 (en) 1993-01-13
MX9203654A (en) 1992-07-01
CA1340978C (en) 2000-05-02
AU579142B2 (en) 1988-11-17
EP0165654A3 (en) 1988-05-04
DK110485D0 (en) 1985-03-11

Similar Documents

Publication Publication Date Title
ATE84547T1 (en) PURIFIED INTERLEUKIN-1.
Allen et al. A family of structural genes for human lymphoblastoid (leukocyte-type) interferon
Narita et al. The amino acid sequence of cardiotoxin from Formosan cobra (Naja naja atra) venom
KR890003802A (en) Bovine pancreatic trypsin inhibitor produced by recombinant DNA technology, methods for preparing the same, expression vectors and recombinant hosts and pharmaceutical uses thereof
EP0538030B1 (en) Novel neutrophil activating factors
WETZEL et al. Properties of a human alpha-interferon purified from E. coli extracts
US5120535A (en) Oncostatin M and novel compositions having anti-neoplastic activity
Travis et al. The amino acid sequence of ferredoxin from the sulfate reducing bacterium, Desulfovibrio gigas
KR880009125A (en) Pancreatic secretive trypsin inhibitors and variants thereof, methods thereof, expression vectors and recombinant hosts and pharmaceutical uses thereof produced by recombinant hosts
Schmelzer et al. Biochemical characterization of recombinant human nerve growth factor
Klippenstein et al. The primary structure of myohemerythrin
KR890000665A (en) Mutant t-PA with Kringle substitution
Proost et al. Chemical synthesis, purification and folding of the human monocyte chemotactic proteins MCP-2 and MCP-3 into biologically active chemokines
ATE163651T1 (en) NEW HUMAN RECOMBINANT INTERFERON GAMMA
Byrne et al. Human granulocyte-macrophage colony-stimulating factor purified from a Hodgkin's tumor cell line
Nagata et al. Purification and characterization of recombinant murine immune interferon
KR940005798A (en) Adipocyte Inhibitory Factor Derivatives, Method of Preparation and Use thereof
US5358707A (en) Oxidized variants of GM-CSF
DE59109085D1 (en) Epididymis-specific polypeptides and their use
Francis et al. Carboxyl-terminal amino acid sequences of two variant forms of the gamma chain of human plasma fibrinogen.
Lauren et al. Covalent dimerization of recombinant human interferon-γ
EP0147175A3 (en) Novel basic polypeptides and a method of producing thereof
Aggarwal et al. [34] Human tumor necrosis factor
Linder et al. Separation of human pancreatic carboxypeptidase A isoenzymes by high performance liquid chromatography
Suzue et al. Cooperarive participation of two peptides from β-casein in leukocyte chemotaxis

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Free format text: BARZ, P., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 80803 MUENCHEN

8327 Change in the person/name/address of the patent owner

Owner name: CISTRON BIOTECHNOLOGY,INC., PINE BROOK, N.J., US

8365 Fully valid after opposition proceedings